Gilead (GILD), Merck (MRK) Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 3/28/2024
Go back to Gilead (GILD), Merck (MRK) Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
March 15, 2021 6:20 AM EDT
Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) are joining forces to develop a long-acting HIV therapy, according to the Wall Street Journal.
...
More